meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
atezolizumab plus pemetrexed and platin
cemiplimab
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab and pemetrexed plus platin
pembrolizumab plus SoC
sintilimab based treatment
sintillimab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
pembrolizumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs nab-paclitaxel
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs pemetrexed plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus carboplatin plus nab-paclitaxel
vs pembrolizumab based treatment
vs pembrolizumab alone
vs pembrolizumab plus placebo
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel
All patients
Age < 65y (younger)
Age > 65y
Age > 75y (older)
Asian type
cell type, non squamous cell
cell type, squamous cell
ECOG 0
ECOG 1
EGFR mutant
Gender, female
Gender, male
metastasis (brain) NO
metastasis (brain) YES
metastasis (liver )
PD-L1 < 1%
PD-L1 > 1%
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC)
PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC)
PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC)
PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )
PDL1 (TPS >50%)
smoker (current or former)
smoker (Current)
smoker (Former)
smoker (never)
stage III (locally advanced)
stage IV (metastatic)
Teff high
Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
deaths (OS) (extension)
DOR
DOR (extension)
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dizziness TRAE (grade 3-4)
Dysgeusia TRAE (grade 3-4)
Epistaxis TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Guillain-Barré syndrome TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lacrimation (TRAE grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pancytopenia TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Peripheral oedema TRAE (grade 3-4)
Peripheral sensory neuropathy TRAE (grade 3-4)
Pneumonia TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Sepsis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
hepatitis (Autoimmune) AE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Agranulocytosis (AE grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Blood creatinine increased AE (grade 3-4)
Colitis AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diabetes mellitus AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dry skin AE (grade 3-4)
Dysgeusia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Epistaxis AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Gastritis AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Hyperthyroidism AE (grade 3-4)
Hypophysitis AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Increased Lipase Level AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Lacrimation increased AE (grade 3-4)
Leucopenia AE (grade 3-4)
Myalgia AE (grade 3-4)
myocarditis AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Pancytopenia (AE grade 3-4)
Paraesthesia AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Peripheral sensory neuropathy AE (grade 3-4)
Pneumonia AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Rash maculopapular AE (grade 3-4)
Sepsis AE (grade 3-4)
Severe skin reactions AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Thyroiditis AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
DCR
mNSCLC - L1 - all population
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
versus placebo plus SoC
sintillimab plus SoC vs. placebo plus SoC
1
-
versus Standard of Care (SoC)
cemiplimab vs. Standard of Care (SoC)
1
-
durvalumab alone vs. Standard of Care (SoC)
1
-
mNSCLC - L1 - PDL1 negative
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - PDL1 negative
versus pemetrexed plus platin
nivolumab plus SoC vs. pemetrexed plus platin
1
-
mNSCLC - L1 - PDL1 positive
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC)
3
-
cemiplimab vs. Standard of Care (SoC)
1
-
durvalumab alone vs. Standard of Care (SoC)
1
-
nivolumab alone vs. Standard of Care (SoC)
2
-
pembrolizumab alone vs. Standard of Care (SoC)
4
-
mNSCLC - L1 - TMB>10Mb
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - TMB
10Mb
non squamous - mNSCLC - L1 - all population
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel
1
-
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
1
-
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
1
-
non squamous - mNSCLC - L1 - Wild Type (WT)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - Wild Type (WT)
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel
2
-
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel
1
-
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin
1
-
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin
1
-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC
1
-
squamous - mNSCLC - L1 - all population
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel
1
-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open